신속 미생물 검사 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of rapid microbiology testing Market

The global rapid microbiology testing market size was valued at USD 6.95 billion in 2025 and is projected to reach USD 7.44 billion in 2026 and USD 13.34 billion by 2034, exhibiting a CAGR of 7.6% during the forecast period. North America dominated the market in 2025, supported by advanced laboratory infrastructure, strong adoption of rapid diagnostics, and favorable regulatory frameworks.

Rapid microbiology testing includes advanced methods used for rapid detection, identification, and quantification of microorganisms. Rising infectious disease prevalence, increasing patient admissions, growing demand for point-of-care diagnostics, and expanding pharmaceutical sterility testing are supporting market growth.

Latest Trends

Technological advancements are transforming rapid microbiology testing through molecular diagnostics, nucleic acid amplification, automation, artificial intelligence, and digital microbiology. Growing demand for faster time-to-result and reduced manual intervention is encouraging laboratories to adopt automated testing workflows. Multiplex testing and molecular assays are also gaining importance because they can improve sensitivity and support rapid identification of multiple pathogens.

Rapid testing is additionally expanding across pharmaceutical and biomanufacturing applications for sterility testing and environmental monitoring. In September 2024, Terumo Corporation and Cell Technologies collaborated with Nova Biomedical to enable automated cell culture sensing through integration of Terumo BCT's Quantum Flex Cell Expansion System with Nova's BioProfile FLEX2 Automated Cell Culture Analyzer.

Market Dynamics

DRIVER - Increasing Prevalence of Infectious Diseases: Growing incidence of infectious diseases is increasing diagnostic testing volumes and supporting demand for rapid microbiology testing. Faster detection can help reduce treatment delays and support earlier clinical intervention.

RESTRAINT - High Cost of Advanced Instruments: Advanced molecular detection systems, viability analyzers, and other sophisticated instruments require significant capital investment. Software integration, regulatory compliance, maintenance, and infrastructure requirements can further increase costs, particularly for smaller laboratories and organizations in emerging markets.

MARKET OPPORTUNITY - Growing Adoption in Emerging Markets: Expanding healthcare infrastructure, increasing diagnostic awareness, and rising demand for reliable microbial detection are creating opportunities across emerging economies. Pharmaceutical and biotechnology manufacturing growth is also supporting demand for rapid testing solutions.

CHALLENGE - Regulatory and Compliance Complexities: Different regulatory requirements across countries can increase documentation, validation, and approval requirements. These complexities may delay adoption and technology transfers, particularly for smaller and mid-sized companies.

Segmentation Analysis

By Product Type: The market is segmented into instruments and reagents & consumables. Instruments held the dominant position in 2025 due to increasing diagnostic testing volumes and technological advancements. Reagents & consumables are projected to expand at a CAGR of 7.7% during the forecast period.

By Method: The market includes nucleic acid based, viability based, biochemical and immunological based, growth based, and others. The nucleic acid based segment is expected to dominate with a 42.1% share in 2026, supported by demand for rapid and accurate diagnostic outcomes.

By Application: Clinical diagnostics, pharmaceutical & biologics manufacturing, and others constitute the application segments. Clinical diagnostics dominated with a 49.9% share in 2025, while pharmaceutical & biologics manufacturing is projected to grow at a CAGR of 8.0%.

By End User: Hospitals & ASCs, clinical laboratories, pharmaceutical & biotechnology companies, and others form the major end-user segments. Hospitals & ASCs dominated in 2025 and are expected to account for a 45.8% share in 2026.

Regional Outlook

North America generated USD 2.70 billion in 2025, maintaining its leading position due to advanced laboratory infrastructure, infectious disease testing demand, and supportive regulatory frameworks. The U.S. market is estimated at USD 2.67 billion in 2026.

Europe reached USD 2.30 billion in 2025 and is projected to grow at a CAGR of 7.3%. The region benefits from its pharmaceutical manufacturing base and increasing demand for rapid quality-control methods.

Asia Pacific recorded USD 1.47 billion in 2025, supported by healthcare infrastructure development, rising patient admissions, and industry consolidation. India reached USD 0.22 billion, while China registered USD 0.48 billion in 2025.

Latin America and Middle East & Africa are expected to experience moderate growth, supported by increasing infectious disease prevalence, healthcare infrastructure development, and demand for advanced diagnostic technologies. Latin America reached USD 0.27 billion, while GCC recorded USD 0.09 billion in 2025.

List of Top Companies

Key companies operating in the rapid microbiology testing market include BIOMERIEUX SA, Danaher Corporation, Thermo Fisher Scientific Inc., Abbott, BD, Bruker, QuidelOrtho Corporation, Charles River Laboratories, Sartorius AG, and Merck KGaA.

Investment Analysis and Opportunities

Investment opportunities are emerging in molecular diagnostics, automated laboratory systems, rapid sterility testing, point-of-care platforms, and AI-enabled microbiology workflows. Strategic acquisitions and partnerships are also helping companies expand technological capabilities and geographic reach.

New Product Development

Companies are focusing on nucleic acid amplification tests, automated microbial detection platforms, rapid sterility testing systems, and integrated laboratory solutions. In September 2025, FUJIFILM Wako Pure Chemical Corporation launched the RiboNAT Rapid Sterility Test based on a nucleic acid amplification method.

Five Recent Developments (2023-2025)

In November 2025, Lonza signed an agreement to acquire Redberry SAS to strengthen rapid microbiology testing capabilities. In May 2025, researchers at Osmania University developed a low-cost rapid diagnostic test using gold nanoparticles for sepsis. In March 2025, Nelson Labs expanded rapid microbiological testing capabilities across multiple laboratory sites. In May 2024, Sherlock Bio initiated trials of an over-the-counter STI rapid test. In January 2024, Samsung Biologics selected Rapid Micro Biosystems' Growth Direct platform for automated microbial quality control.

Report Coverage

The Rapid Microbiology Testing Market Report provides a detailed Market Analysis covering product type, method, application, end user, regional performance, competitive landscape, Market Trends, Market Growth, Market Opportunities, and key industry developments. It also highlights the factors influencing the Market Outlook and future demand for rapid microbiology testing technologies.

Conclusion

The rapid microbiology testing market is progressing as healthcare providers, laboratories, and pharmaceutical manufacturers seek faster, automated, and reliable microbial detection. The USD 6.95 billion market size in 2025, projected USD 7.44 billion market value in 2026, and forecast USD 13.34 billion market size by 2034 reflect expanding demand across clinical diagnostics and industrial quality-control applications. Advances in molecular testing, automation, point-of-care diagnostics, and rapid sterility testing are expected to remain important areas of market development.

Segmentation By Product Type, Method, Application, End User, and Region

By Product Type

• Instruments
  • Automated Blood Culture Systems
  • Mass Spectrometers
  • PCR Systems
  • Bioluminescence & Fluorescence-based Detection Systems
• Others
• Reagents & Consumables

By Method

• Nucleic Acid Based
• Viability Based
• Biochemical and Immunological Based
• Growth Based
• Others

By Application

• Clinical Diagnostics
• Pharmaceutical & Biologics Manufacturing
• Others

By End User

• Hospitals & ASCs
• Clinical Laboratories
• Pharmaceutical & Biotechnology Companies
• Others

By Region

• North America (By Product Type, By Method, By Application, By End User, and by Country)
  • U.S. (By Application)
  • Canada (By Application)
• Europe (By Product Type, By Method, By Application, By End User, and by Country/Sub-region)
  • U.K. (By Application)
  • Germany (By Application)
  • France (By Application)
  • Italy (By Application)
  • Spain (By Application)
  • Scandinavia (By Application)
  • Rest of Europe (By Application)
• Asia Pacific (By Product Type, By Method, By Application, By End User, and by Country/Sub-region)
  • China (By Application)
  • Japan (By Application)
  • India (By Application)
  • Australia (By Application)
  • Southeast Asia (By Application)
  • Rest of Asia Pacific (By Application)
• Latin America (By Product Type, By Method, By Application, By End User, and by Country/Sub-region)
  • Brazil (By Application)
  • Mexico (By Application)
  • Rest of Latin America (By Application)
  • Middle East & Africa (By Product Type, By Method, By Application, By End User, and by Country/Sub-region)
  • GCC (By Application)
  • South Africa (By Application)
• Rest of the Middle East & Africa (By Application)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Disorders, Key Countries/Regions, 2023/2025
• 4.2. Technological Advancements in Rapid Microbiology Testing Products
• 4.3. New Product Launches, Key Players
• 4.4. Key Industry Developments - Mergers, Acquisitions & Partnerships

5. Global Rapid Microbiology Testing Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product Type
  • 5.1.1. Instruments
    • 5.1.1.1. Automated Blood Culture Systems
    • 5.1.1.2. Mass Spectrometers
    • 5.1.1.3. PCR Systems
    • 5.1.1.4. Bioluminescence & Fluorescence-based Detection Systems
    • 5.1.1.5. Others
  • 5.1.2. Reagents & Consumables
• 5.2. Market Analysis, Insights and Forecast - By Method
  • 5.2.1. Nucleic Acid Based
  • 5.2.2. Viability Based
  • 5.2.3. Biochemical and Immunological Based
  • 5.2.4. Growth Based
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Application
  • 5.3.1. Clinical Diagnostics
  • 5.3.2. Pharmaceutical & Biologics Manufacturing
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Hospitals & ASCs
  • 5.4.2. Clinical Laboratories
  • 5.4.3. Pharmaceutical & Biotechnology Companies
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Rapid Microbiology Testing Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product Type
  • 6.1.1. Instruments
    • 6.1.1.1. Automated Blood Culture Systems
    • 6.1.1.2. Mass Spectrometers
    • 6.1.1.3. PCR Systems
    • 6.1.1.4. Bioluminescence & Fluorescence-based Detection Systems
    • 6.1.1.5. Others
  • 6.1.2. Reagents & Consumables
• 6.2. Market Analysis, Insights and Forecast - By Method
  • 6.2.1. Nucleic Acid Based
  • 6.2.2. Viability Based
  • 6.2.3. Biochemical and Immunological Based
  • 6.2.4. Growth Based
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By Application
  • 6.3.1. Clinical Diagnostics
  • 6.3.2. Pharmaceutical & Biologics Manufacturing
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By End User
  • 6.4.1. Hospitals & ASCs
  • 6.4.2. Clinical Laboratories
  • 6.4.3. Pharmaceutical & Biotechnology Companies
  • 6.4.4. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
    • 6.5.1.1. By Application
  • 6.5.2. Canada
    • 6.5.2.1. By Application

7. Europe Rapid Microbiology Testing Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product Type
  • 7.1.1. Instruments
    • 7.1.1.1. Automated Blood Culture Systems
    • 7.1.1.2. Mass Spectrometers
    • 7.1.1.3. PCR Systems
    • 7.1.1.4. Bioluminescence & Fluorescence-based Detection Systems
    • 7.1.1.5. Others
  • 7.1.2. Reagents & Consumables
• 7.2. Market Analysis, Insights and Forecast - By Method
  • 7.2.1. Nucleic Acid Based
  • 7.2.2. Viability Based
  • 7.2.3. Biochemical and Immunological Based
  • 7.2.4. Growth Based
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By Application
  • 7.3.1. Clinical Diagnostics
  • 7.3.2. Pharmaceutical & Biologics Manufacturing
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By End User
  • 7.4.1. Hospitals & ASCs
  • 7.4.2. Clinical Laboratories
  • 7.4.3. Pharmaceutical & Biotechnology Companies
  • 7.4.4. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.5.1. U.K.
    • 7.5.1.1. By Application
  • 7.5.2. Germany
    • 7.5.2.1. By Application
  • 7.5.3. France
    • 7.5.3.1. By Application
  • 7.5.4. Spain
    • 7.5.4.1. By Application
  • 7.5.5. Italy
    • 7.5.5.1. By Application
  • 7.5.6. Scandinavia
    • 7.5.6.1. By Application
  • 7.5.7. Rest of Europe
    • 7.5.7.1. By Application

8. Asia Pacific Rapid Microbiology Testing Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product Type
  • 8.1.1. Instruments
    • 8.1.1.1. Automated Blood Culture Systems
    • 8.1.1.2. Mass Spectrometers
    • 8.1.1.3. PCR Systems
    • 8.1.1.4. Bioluminescence & Fluorescence-based Detection Systems
    • 8.1.1.5. Others
  • 8.1.2. Reagents & Consumables
• 8.2. Market Analysis, Insights and Forecast - By Method
  • 8.2.1. Nucleic Acid Based
  • 8.2.2. Viability Based
  • 8.2.3. Biochemical and Immunological Based
  • 8.2.4. Growth Based
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By Application
  • 8.3.1. Clinical Diagnostics
  • 8.3.2. Pharmaceutical & Biologics Manufacturing
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By End User
  • 8.4.1. Hospitals & ASCs
  • 8.4.2. Clinical Laboratories
  • 8.4.3. Pharmaceutical & Biotechnology Companies
  • 8.4.4. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.5.1. Japan
    • 8.5.1.1. By Application
  • 8.5.2. Australia
    • 8.5.2.1. By Application
  • 8.5.3. China
    • 8.5.3.1. By Application
  • 8.5.4. India
    • 8.5.4.1. By Application
  • 8.5.5. Southeast Asia
    • 8.5.5.1. By Application
  • 8.5.6. Rest of Asia Pacific
    • 8.5.6.1. By Application

9. Latin America Rapid Microbiology Testing Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product Type
  • 9.1.1. Instruments
    • 9.1.1.1. Automated Blood Culture Systems
    • 9.1.1.2. Mass Spectrometers
    • 9.1.1.3. PCR Systems
    • 9.1.1.4. Bioluminescence & Fluorescence-based Detection Systems
    • 9.1.1.5. Others
  • 9.1.2. Reagents & Consumables
• 9.2. Market Analysis, Insights and Forecast - By Method
  • 9.2.1. Nucleic Acid Based
  • 9.2.2. Viability Based
  • 9.2.3. Biochemical and Immunological Based
  • 9.2.4. Growth Based
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By Application
  • 9.3.1. Clinical Diagnostics
  • 9.3.2. Pharmaceutical & Biologics Manufacturing
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By End User
  • 9.4.1. Hospitals & ASCs
  • 9.4.2. Clinical Laboratories
  • 9.4.3. Pharmaceutical & Biotechnology Companies
  • 9.4.4. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.5.1. Brazil
    • 9.5.1.1. By Application
  • 9.5.2. Mexico
    • 9.5.2.1. By Application
  • 9.5.3. Rest of Latin America
    • 9.5.3.1. By Application

10. Middle East & Africa Rapid Microbiology Testing Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product Type
  • 10.1.1. Instruments
    • 10.1.1.1. Automated Blood Culture Systems
    • 10.1.1.2. Mass Spectrometers
    • 10.1.1.3. PCR Systems
    • 10.1.1.4. Bioluminescence & Fluorescence-based Detection Systems
    • 10.1.1.5. Others
  • 10.1.2. Reagents & Consumables
• 10.2. Market Analysis, Insights and Forecast - By Method
  • 10.2.1. Nucleic Acid Based
  • 10.2.2. Viability Based
  • 10.2.3. Biochemical and Immunological Based
  • 10.2.4. Growth Based
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By Application
  • 10.3.1. Clinical Diagnostics
  • 10.3.2. Pharmaceutical & Biologics Manufacturing
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By End User
  • 10.4.1. Hospitals & ASCs
  • 10.4.2. Clinical Laboratories
  • 10.4.3. Pharmaceutical & Biotechnology Companies
  • 10.4.4. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.5.1. GCC
    • 10.5.1.1. By Application
  • 10.5.2. South Africa
    • 10.5.2.1. By Application
  • 10.5.3. Rest of Middle East & Africa
    • 10.5.3.1. By Application

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. BIOMERIEUX SA
  • 11.2.2. Danaher Corporation
  • 11.2.3. Thermo Fisher Scientific Inc.
  • 11.2.4. Abbott
  • 11.2.5. BD
  • 11.2.6. Bruker
  • 11.2.7. QuidelOrtho Corporation
  • 11.2.8. Charles River Laboratories
  • 11.2.9. Sartorius AG
  • 11.2.10. Merck KGaA